Nalbuphine tablets for cough in patients with idiopathic pulmonary fibrosis

This randomized, double-blind, placebo-controlled, crossover trial evaluated the efficacy and safety of nalbuphine extended-release tablets for the treatment of cough in 41 in patients with IPF. The primary endpoint was the percent change from baseline in objective hourly daytime (ie awake) cough frequency, which was measured using the Vitalograph VitaloJAK electronic cough monitor. Secondary endpoints included change in objective 24-hour cough frequency and changes in patient-reported cough frequency, cough severity, and breathlessness.